Compare Nike Inc (NKE) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nike Inc vs Repligen Corporation Common Stock — how do they compare? Nike Inc trades at $35.43 (market cap $52.43B), while Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B). The key difference: Nike Inc is far larger — about 4.6× Repligen Corporation Common Stock's market cap, and Nike Inc pays a 4.65% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nike Inc for 155 Days and Repligen Corporation Common Stock for 0 Days on average.
| NKE | RGEN | |
|---|---|---|
Market Cap | $52.43B | $11.31B |
Volume | 19,378,123 | 1,216,919 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.68 | $194.57 |
52-Week Low | $33.87 | $102.87 |
Typical Hold Time | 155 Days | 0 Days |
Enterprise Value | $55.14B | $11.20B |
Dividend Yield | 4.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NKE trades at $35.33, down slightly (-0.06%) on the day, with a bearish technical signal. The stock has a P/E of 16.9 and P/S of 1.14, trading below the analyst consensus price target of $36.80. Recent earnings have consistently beaten expectations, but revenue and net income have declined year-over-year. The company maintains strong brand equity but faces headwinds in key markets like China.
NKE's investment case hinges on its brand strength and potential for a turnaround, but near-term risks include sluggish consumer demand and margin pressure. The stock offers a dividend yield, but investors should weigh the execution risks of its strategic initiatives against its current valuation.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
